RxDoctor Payments Data

Diana Crook, MD

Family Medicine · Wichita, KSNPI 1679530760

Payments from drug & device makers

$10,662in general payments, 2019–2025

Across 355 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • AbbVie$907
  • Johnson & Johnson$592
  • Lilly USA, LLC$525
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,51399%
  • Education$1491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,662 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$125,300
Medicare patients
240
Services billed
2,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$55,451
FarxigaDapagliflozin Propanediol72$46,118
EliquisApixaban71$44,158
MounjaroTirzepatide25$29,340
JardianceEmpagliflozin21$23,059
JanuviaSitagliptin Phosphate13$17,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,740
Breo ElliptaFluticasone/Vilanterol35$14,380
TrulicityDulaglutide14$13,441
GemtesaVibegron20$13,336
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$9,582
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,411
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,977
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,417
MyrbetriqMirabegron13$6,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,523$55,53087 claims
Novo NordiskOzempic$1,371$55,45151 claims
PfizerEliquis$186$44,15871 claims
Lilly USA, LLCMounjaro, Trulicity$525$42,78139 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$472$36,53784 claims
Boehringer IngelheimJardiance, Stiolto Respimat$28$32,03632 claims
MerckJanuvia$147$17,54913 claims
Astellas Pharma US IncMyrbetriq$165$6,93513 claims
AbbVieSynthroid$907$4,31439 claims
Eisai Inc.Dayvigo$21$3,96312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →